candesartan (Atacand)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradname: Atacand. (candesartan cilexetil) Generic Dec 2012[8]

Indications

* Only irbesartan (Avapro) & losartan (Cozaar) shown to have beneficial effects[3]; candesartan probably does as well

# measured by Trail Making Test Part B[9]

Contraindications

Dosage

  • start: 16 mg QD when used as monotherapy
  • CHF: start 4-8 mg QD; max 32 mg QD

Tabs: 4, 8, 16, 32 mg.

Addition of 12.5 mg of HCTZ may improve BP response.

Dosage adjustment in renal failure

Pharmacokinetics

Adverse effects

Mechanism of action

More general terms

Additional terms

Component of

References

  1. Internal Medicine Alert 20(21):165 1998
  2. 2.0 2.1 Journal Watch 23(4):34, 2003 Tronvik E et al, JAMA 289:65, 2003
  3. 3.0 3.1 Prescriber's Letter 9(11):61 2002
  4. 4.0 4.1 Journal Watch 23(21):165, 2003
  5. 5.0 5.1 Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S; CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA. 2005 Oct 12;294(14):1794-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16219883
  6. 6.0 6.1 Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  7. 7.0 7.1 Chaturvedi N et al, Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet. 2008 Oct 18;372(9647):1394-402. Epub 2008 Sep 25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18823656
    Sjolie AK et al, Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet. 2008 Oct 18;372(9647):1361-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18823658
  8. 8.0 8.1 8.2 Prescriber's Letter 19(4): 2012 CHART: Anticipated Availability of First-Time Generics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280401&pb=PRL (subscription needed) http://www.prescribersletter.com
  9. 9.0 9.1 9.2 Lou N ARB Slows Cognitive Decline in Trial... But How? - Consequence of lowered blood pressure, or perhaps a direct effect -- or just a fluke Mhttps://www.medpagetoday.com/neurology/dementia/87929
    Hajjar I, Okafor M, McDaniel D et al ffects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment. A Randomized Clinical Trial. JAMA Netw Open. 2020;3(8):e2012252. August 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32761160 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769104
  10. 10.0 10.1 Sanchez-Rodriguez C, Sierra A, Planchuelo-Gomez A et al Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep. 2021 Feb 15;11(1):3846. doi:http://dx.doi.org/ 10.1038/s41598-021-83508-2. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33589682 Free PMC article.

Database